Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-05-15
2007-05-15
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S074000
Reexamination Certificate
active
10474592
ABSTRACT:
There is provided substantially crystalline forms of 4-({3-[7-(3,3-dimethyl-2-oxobutyl) -9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]propyl}amino)benzo-nitrile; tert-butyl 2 -{7-[3-(4-cyanoanilino)propyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate; tert-butyl 2-{7-[4-(4-cyanophenyl)butyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl}ethylcarbamate; or tert-butyl 2-{7-[2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo-[3.3.1]non-3-yl}ethylcarbamate and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of cardiac arhythmias.
REFERENCES:
patent: 6559143 (2003-05-01), Bjore et al.
patent: 0 308 843 (1988-09-01), None
patent: WO-91/07405 (1991-05-01), None
patent: WO-99/31100 (1999-06-01), None
patent: WO-00/77000 (2000-12-01), None
patent: WO-01/28992 (2001-04-01), None
DeRuiter, J., et al., “Synthesis and in Vitro Aldose Reductase Inhibitory Activity of Compounds Containing an N-Acylglycine Moiety,” J. Med. Chem.., 32, 1033-1038 (1989).
Dudley, K., et al., “Chemical Studies of Potential Relevance to Penicillin Hypersensitivity. The Synthesis of DL-2 Phenoxymethylpenicillenic Acid and of DL-2-(2,6-Dimethoxyphenyl)penicillenic Acid(1),” J. Heterocyclic Chem., 10, 935-941 (1975).
Ginzel, K., et al., “Indirect Electrochemical a-Methoxylation of N-Acyl and N-Carboalkoxy a-Amino Acid Esters and Application as Cationic Glycine Equivalents,” Tetrahedron, 45(6), 1691-1701 (1989).
Davis, F., et al., “Asymmetric Synthesis of 2H-Azirine 2-Carboxylate Esters,” J. Org. Chem., 64, 8929-8935 (1999).
Paolo, C., “Swelling-controlled release in hydrogel matrices for oral route,” Advanced Drug Delivery Reviews, 11, 37-57 (1993).
Paudler et al., “3,7-Disubstituted Octahydro-1,5-diazocines. Their Conversion into Tetrahydro-1,5-diazocines and into Ring-Contracted Products,” J. Org. Chem. 32:2425-2430 (1967).
Barnwell Neil
Björe Annika
Cheema Lal
Cladingboel David
Herring Adam
Astrazeneca AB
Christer Hallgren Pepper Hamilton LLP
Habte Kahsay
LandOfFree
3,7-Diazabicyclo [3.3.1] formulations as anti-arrhythmic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,7-Diazabicyclo [3.3.1] formulations as anti-arrhythmic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,7-Diazabicyclo [3.3.1] formulations as anti-arrhythmic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3778279